DiaMedica Therapeutics (DMAC) Total Non-Current Liabilities (2018 - 2026)
DiaMedica Therapeutics' (DMAC) quarterly Total Non-Current Liabilities came in at $97000.0 in Q1 2026, down 54.03% year-on-year from $211000.0 in Q1 2025, and down 24.22% quarter-over-quarter from $128000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $97000.0 for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 54.03% year-over-year to $97000.0 in Q1 2026; TTM through Mar 2026 was $97000.0, a 54.03% decrease from a year earlier, with the FY2025 full-year figure at $128000.0, down 45.99% from the prior year.
- Total Non-Current Liabilities fell to $97000.0 in Q1 2026 per DMAC's latest filing, from $128000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $420000.0 in Q3 2022 and bottomed at $7000.0 in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $263000.0 (2024), against an average of $240823.5.
- Biggest YoY gain for Total Non-Current Liabilities was 13233.33% in 2022; the steepest drop was 72.73% in 2022.
- Year by year, Total Non-Current Liabilities stood at $400000.0 in 2022, then dropped by 20.75% to $317000.0 in 2023, then fell by 25.24% to $237000.0 in 2024, then tumbled by 45.99% to $128000.0 in 2025, then decreased by 24.22% to $97000.0 in 2026.
- Per Business Quant, the three latest DMAC Total Non-Current Liabilities figures stand at $97000.0 (Q1 2026), $128000.0 (Q4 2025), and $157000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | DiaMedica Therapeutics | 366.87 Mn | 366.87 Mn | - | 97,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 97,000.00 |
| Dec 31, 2025 | 128,000.00 |
| Sep 30, 2025 | 157,000.00 |
| Jun 30, 2025 | 184,000.00 |
| Mar 31, 2025 | 211,000.00 |
| Dec 31, 2024 | 237,000.00 |
| Sep 30, 2024 | 263,000.00 |
| Jun 30, 2024 | 288,000.00 |
| Mar 31, 2024 | 294,000.00 |
| Dec 31, 2023 | 317,000.00 |
| Sep 30, 2023 | 340,000.00 |
| Jun 30, 2023 | 361,000.00 |
| Mar 31, 2023 | 381,000.00 |
| Dec 31, 2022 | 400,000.00 |
| Sep 30, 2022 | 420,000.00 |
| Jun 30, 2022 | 7,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | 3,000.00 |
| Sep 30, 2021 | 4,000.00 |
| Jun 30, 2021 | 16,000.00 |